Clinical trial

MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer

NCT06735508

View saved research
StatusNOT_YET_RECRUITING
Study typeINTERVENTIONAL
Start date2025-01-01
PhaseEARLY_PHASE1

Study timeline

Study start (estimated)2025-01-01Date precision: month
Registry last updated2024-12-16
Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

What this registered study describes

MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer is a interventional study listed under registry identifier NCT06735508. Its last published status is NOT YET RECRUITING. Registry status does not establish that enrollment is currently open at every study site.

The published record lists 1 condition label(s), 2 intervention label(s), and 2 sponsor/collaborator entry or entries. The structured information below allows these links to be examined individually; intervention registration is not an efficacy claim.

Source: the original ClinicalTrials.gov study record. Always check the protocol, eligibility, dates, results (when posted), and contacts at the original source.

Clinical trial site map

Published registry research cities for this specific study. Pins represent city-level locations, not exact facility addresses. Confirm current enrollment and facility details with the study team.

1 published city locations shown (maximum 300). Some registry locations may not have coordinates or may not be published yet.

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.